What can we learn about valvular heart disease from PET/CT?

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet368(9540),1005–1011 (2006).
  MedlineGoogle Scholar
• 2  Dweck MR, Jones C, Joshi NV et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation125(1),76–86 (2012).▪▪ Largest study to date assessing 18F-fluorodeoxyglucose (18F-FDG) and 18F-sodium flouride as markers of inflammation and calcification activity in the valves of patients with aortic stenosis.
  Medline CASGoogle Scholar
• 3  Millar BC, Prendergast BD, Alavi A, Moore JE. 18FDG-positron emission tomography (PET) has a role to play in the diagnosis and therapy of infective endocarditis and cardiac device infection. Int. J. Cardiol.pii: S0167–S5273(12),01633–01636 (2013).
  Google Scholar
• 4  Rudd JHF, Myers KS, Bansilal S et al. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible. J. Am. Coll. Cardiol.50(9),892–896 (2007).
  MedlineGoogle Scholar
• 5  van den Borne SWM, Isobe S, Verjans JW et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J. Am. Coll. Cardiol.52(24),2017–2028 (2008).▪ Highlights the potential that nuclear imaging of integrin expression holds in predicting the extent of myocardial remodeling and scar formation postmyocardial infarction.
  Medline CASGoogle Scholar
• 6  Gaemperli O, Kaufmann PA. PET and PET/CT in cardiovascular disease. Ann. NY Acad. Sci.1228(1),109–136 (2011).
  Medline CASGoogle Scholar
• 7  Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J. Nucl. Med.49(Suppl. 2),S5–S23 (2008).
  MedlineGoogle Scholar
• 8  Berman DS, Germano G, Slomka PJ. Improvement in PET myocardial perfusion image quality and quantification with flurpiridaz F 18. J. Nucl. Cardiol.19(Suppl. 1),S38–S45 (2012).
  MedlineGoogle Scholar
• 9  Woo J, Tamarappoo B, Dey D et al. Automatic 3D registration of dynamic stress and rest 82Rb and flurpiridaz F 18 myocardial perfusion PET data for patient motion detection and correction. Med. Phys.38(11),6313 (2011).
  Medline CASGoogle Scholar
• 10  Kaneko K, Kawasaki T, Masunari S, Yoshida T, Omagari J. Determinants of extraaortic arterial 18F-FDG accumulation in asymptomatic cohorts: sex differences in the association with cardiovascular risk factors and coronary artery stenosis. J. Nucl. Med.54(4),564–570 (2013).
  Medline CASGoogle Scholar
• 11  Rudd JH, Warburton EA, Fryer TD et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation105(23),2708–2711 (2002).
  Medline CASGoogle Scholar
• 12  Tawakol A, Migrino RQ, Bashian GG et al.In vivo 18F fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol.48(9),1818–1824 (2006).
  MedlineGoogle Scholar
• 13  Saam T, Rominger A, Wolpers S et al. Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study. Eur. J. Nucl. Med. Mol. Imaging37(6),1203–1212 (2010).
  MedlineGoogle Scholar
• 14  Marnane M, Merwick A, Sheehan OC et al. Carotid plaque inflammation on ¹⁸F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann. Neurol.71(5),709–718 (2012).
  MedlineGoogle Scholar
• 15  Paulmier B, Duet M, Khayat R et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J. Nucl. Cardiol.15(2),209–217 (2008).
  MedlineGoogle Scholar
• 16  Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis. J. Am. Coll. Cardiol.60(19),1854–1863 (2012).
  MedlineGoogle Scholar
• 17  Marincheva-Savcheva G, Subramanian S, Qadir S et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol.57(25),2507–2515 (2011).
  MedlineGoogle Scholar
• 18  Williams G, Kolodny GM. Suppression of myocardial ¹⁸F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. Am. J. Roentgenol.190(2),W151–W156 (2008).▪▪ Key paper in 18F-FDG positron emission tomography cardiac imaging, stipulating the importance of carbohydrate fasting in reducing myocardial 18F-FDG uptake.
  MedlineGoogle Scholar
• 19  Cook GJ, Blake GM, Marsden PK, Cronin B, Fogelman I. Quantification of skeletal kinetic indices in paget’s disease using dynamic 18F-fluoride positron emission tomography. J. Bone Miner. Res.17(5),854–859 (2002).
  Medline CASGoogle Scholar
• 20  Frost ML, Fogelman I, Blake GM, Marsden PK, Cook G. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J. Bone Miner. Res.19(11),1797–1804 (2004).
  Medline CASGoogle Scholar
• 21  Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J. Nucl. Med.49(1),68–78 (2008).
  MedlineGoogle Scholar
• 22  Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circulation Res.89(12),1147–1154 (2001).
  Medline CASGoogle Scholar
• 23  Kaden JJ, Bickelhaupt S, Grobholz R et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J. Mol. Cell. Cardiol.36(1),57–66 (2004).
  Medline CASGoogle Scholar
• 24  Kaden JJ, Kiliç R, Sarikoç A et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int. J. Mol. Med.16(5),869–872 (2005).
  Medline CASGoogle Scholar
• 25  Steiner I, Kasparová P, Kohout A, Dominik J. Bone formation in cardiac valves: a histopathological study of 128 cases. Virchows Arch.450(6),653–657 (2007).
  MedlineGoogle Scholar
• 26  Cowell SJ, Newby DE, Burton J et al. Aortic valve calcification on computed tomography predicts the severity of aortic stenosis. Clin. Radiol.58(9),5 (2003).
  Google Scholar
• 27  Davies SW, Gershlick AH, Balcon RR. Progression of valvar aortic stenosis: a long-term retrospective study. Eur. Heart J.12(1),10–14 (1991).
  Medline CASGoogle Scholar
• 28  Rosenhek RR, Binder TT, Porenta GG et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N. Engl. J. Med.343(9),611–617 (2000).
  Medline CASGoogle Scholar
• 29  Hyafil F, Messika-Zeitoun D, Burg S et al. Detection of 18fluoride sodium accumulation by positron emission tomography in calcified stenotic aortic valves. Am. J. Cardiol.109(8),1194–1196 (2012).
  MedlineGoogle Scholar
• 30  Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol. J. Am. Coll. Cardiol.57(16),1666–1675 (2011).
  Medline CASGoogle Scholar
• 31  Cowell SJ, Newby DE, Robin J et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med.352,2389–2397 (2005).
  Medline CASGoogle Scholar
• 32  Carabello BA. The SEAS trial. Curr. Cardiol. Rep.12(2),122–124 (2010).
  MedlineGoogle Scholar
• 33  Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation121(2),306–314 (2010).
  Medline CASGoogle Scholar
• 34  Dweck MR, Khaw HJ, Sng GKZ et al. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur. Heart J.34(21),1567–1574 (2013).
  Medline CASGoogle Scholar
• 35  Ben-Haim S, Gacinovic S, Israel O. Cardiovascular infection and inflammation. Semin. Nucl. Med.39(2),103–114 (2009).
  MedlineGoogle Scholar
• 36  Takano H, Nakagawa K, Ishio N et al. Active myocarditis in a patient with chronic active Epstein–Barr virus infection. Int. J. Cardiol.130(1),e11–e13 (2008).
  MedlineGoogle Scholar
• 37  Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin. Rheumatol.30(10),1265–1275 (2011).
  MedlineGoogle Scholar
• 38  Fisk M, Peck LF, Miyagi K et al. Mycotic aneurysms: a case report, clinical review and novel imaging strategy. QJM105(2),181–188 (2012).
  Medline CASGoogle Scholar
• 39  Marion MD, Swanson MK, Spellman J, Spieth ME. Femoropopliteal prosthetic bypass graft infection due to Mycobacterium abscessus localized by FDG-PET/CT scan. J. Vasc. Surg.50(4),907–909 (2009).
  MedlineGoogle Scholar
• 40  Spacek M, Belohlavek O, Votrubova J, Sebesta P, Stadler P. Diagnostics of “non-acute” vascular prosthesis infection using 18F-FDG PET/CT: our experience with 96 prostheses. Eur. J. Nucl. Med. Mol. Imaging36(5),850–858 (2008).
  MedlineGoogle Scholar
• 41  Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDG PET/CT. J. Nucl. Med.49(12),1980–1985 (2008).
  MedlineGoogle Scholar
• 42  van der Bruggen W. PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. Semin. Nucl. Med.40,3–15 (2010).
  MedlineGoogle Scholar
• 43  Zhuang H, Yang H, Alavi A. Critical role of ¹⁸F-labeled fluorodeoxyglucose PET in the management of patients with arthroplasty. Radiol. Clin. North Am.45(4),711–718 (2007).
  MedlineGoogle Scholar
• 44  Durack DT, Lukes AS, Bright DK, Duke Endocarditis Service. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am. J. Med.96(3),200–209 (1994).
  Medline CASGoogle Scholar
• 45  Yen RF, Chen YC, Wu YW, Pan MH, Chang SC. Using 18-fluoro-2-deoxyglucose positron emission tomography in detecting infectious endocarditis/endoarteritis – a preliminary report. Acad. Radiol.11(3),316–321 (2004).
  MedlineGoogle Scholar
• 46  Kouijzer IJ, Vos FJ, Janssen MJ, Dijk AP, Oyen WJ, Bleeker-Rovers CP. The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur. J. Nucl. Med. Mol. Imaging40(7),1102–1107 (2013).▪ First prospective study assessing the diagnostic capabilities of 18F-FDG positron emission tomography in infective endocarditis.
  Medline CASGoogle Scholar
• 47  Van Riet J, Hill EE, Gheysens O et al.¹⁸F-FDG PET/CT for early detection of embolism and metastatic infection in patients with infective endocarditis. Eur. J. Nucl. Med. Mol. Imaging37,1189–1197 (2010).
  MedlineGoogle Scholar
• 48  Potpara TS, Vasiljevic ZM, Vujisic-Tesic BD et al. Mitral annular calcification predicts cardiovascular morbidity and mortality in middle-aged patients with atrial fibrillation: the belgrade atrial fibrillation study. Chest140(4),902–910 (2011).
  MedlineGoogle Scholar
• 49  Allison MA, Cheung P, Criqui MH, Langer RD, Wright CM. Mitral and aortic annular calcification are highly associated with systemic calcified atherosclerosis. Circulation113(6),861–866 (2006).
  MedlineGoogle Scholar
• 50  James OG, Christensen JD, Wong TZ, Borges-Neto S, Koweek LM. Utility of FDG PET/CT in inflammatory cardiovascular disease. Radiographics31(5),1271–1286 (2011).
  MedlineGoogle Scholar
• 51  Camici PG, Rimoldi OE, Gaemperli O, Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur. Heart J.33(11),1309–1317 (2012).
  MedlineGoogle Scholar
• 52  Gaemperli O, Shalhoub J, Owen DR et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur. Heart J.33(15),1902–1910 (2012).
  Medline CASGoogle Scholar
• 53  Kreisl WC, Fujita M, Fujimura Y et al. Comparison of [(11)C]–(R)–PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage49(4),2924–2932 (2010).
  Medline CASGoogle Scholar
• 54  Fujimura Y, Hwang PM, Trout H 3rd et al. Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [3H]PK 11195. Atherosclerosis201(1),108–111 (2008).
  Medline CASGoogle Scholar
• 55  Rominger A, Saam T, Vogl E et al.In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J. Nucl. Med.51(2),193–197 (2010).
  MedlineGoogle Scholar
• 56  Alam SR, Shah ASV, Richards J et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction clinical perspective. Circ. Cardiovasc. Imaging5(5),559–565 (2012).
  MedlineGoogle Scholar
• 57  Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation117(3),379–387 (2008).
  Medline CASGoogle Scholar
• 58  Panizzi P, Nahrendorf M, Figueiredo JL et al.In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat. Med.17(9),1142–1146 (2011).
  Medline CASGoogle Scholar
• 59  Lygoe KA, Norman JT, Marshall JF, Lewis MP. Alphav integrins play an important role in myofibroblast differentiation. Wound Repair Regen.12(4),461–470 (2004).
  MedlineGoogle Scholar
• 60  Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp. Cell Res.312(5),651–658 (2006).
  Medline CASGoogle Scholar
• 61  Antonov AS, Kolodgie FD, Munn DH, Gerrity RG. Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis. Am. J. Pathol.165(1),247–258 (2004).
  Medline CASGoogle Scholar
• 62  Luzina IG, Todd NW, Nacu N et al. Regulation of pulmonary inflammation and fibrosis through expression of integrins αvβ3 and αvβ5 on pulmonary T lymphocytes. Arthritis Rheum.60(5),1530–1539 (2009).
  MedlineGoogle Scholar
• 63  Soini Y, Salo T, Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum. Pathol.34(8),756–763 (2003).
  Medline CASGoogle Scholar
• 64  Akahori H, Tsujino T, Naito Yet al. Intraleaflet haemorrhage is associated with rapid progression of degenerative aortic valve stenosis. Eur. Heart J.32(7),888–896 (2011).
  MedlineGoogle Scholar
• 65  Rodriguez-Porcel MM, Cai WW, Gheysens OO et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J. Nucl. Med.49(4),667–673 (2008).
  MedlineGoogle Scholar
• 66  Rodriguez-Porcel M. Noninvasive monitoring of myocardial angiogenesis. Curr. Cardiovasc. Imaging Rep.2(1),59–66 (2009).
  MedlineGoogle Scholar
• 67  Fondard O. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur. Heart J.26(13),1333–1341 (2005).
  Medline CASGoogle Scholar
• 68  Waters EA, Chen J, Allen JS, Zhang H, Lanza GM, Wickline SA. Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J. Cardiovasc. Magn. Reson.10(1),43 (2008).
  MedlineGoogle Scholar
• 69  Eriksen HA, Satta J, Risteli J, Veijola M, Väre P, Soini Y. Type I and Type III collagen synthesis and composition in the valve matrix in aortic valve stenosis. Atherosclerosis189(1),91–98 (2006).
  Medline CASGoogle Scholar
• 70  Hein S. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation107(7),984–991 (2003).
  MedlineGoogle Scholar
• 71  Dweck MR, Joshi S, Murigu T et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J. Am. Coll. Cardiol.58(12),1271–1279 (2011).▪▪ Introduces the prognostic significance of myocardial fibrosis in aortic stenosis.
  MedlineGoogle Scholar
• 72  Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting v 3 integrin expression, in a patient after acute myocardial infarction. Eur. Heart J.29(18),2201 (2008).
  MedlineGoogle Scholar
• 73  Verjans J, Wolters S, Laufer W et al. Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging. J. Nucl. Cardiol.17(6),1065–1072 (2010).
  MedlineGoogle Scholar
• 74  Fukushima K, Bravo PE, Higuchi T et al. Molecular hybrid positron emission tomography/computed tomography imaging of cardiac angiotensin II type 1 receptors. J. Am. Coll. Cardiol.60(24),2527–2534 (2012).
  Medline CASGoogle Scholar
• 75  Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol.148(7),2207–2216 (1992).
  Medline CASGoogle Scholar
• 76  Kietselaer BL, Reutelingsperger CP, Heidendal GAK et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N. Engl. J. Med.350(14),1472–1473 (2004).
  Medline CASGoogle Scholar
• 77  Kietselaer BL, Reutelingsperger CP, Boersma HH et al. Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. J. Nucl. Med.48(4),562–567 (2007).
  Medline CASGoogle Scholar
• 78  Saraste A, Knuuti J. Cardiac PET, CT, and MR: what are the advantages of hybrid imaging? Curr. Cardiol. Rep.14(1),24–31 (2012).
  MedlineGoogle Scholar
• 79  Pibarot P, Larose É, Dumesnil J. Imaging of valvular heart disease. Can. J. Cardiol.29(3),337–349 (2013).
  MedlineGoogle Scholar